Innovus Pharmaceuticals Inc.


Ticker Symbol: INNV

Innovus Pharmaceuticals Inc. (OTCQB: INNV) is an emerging leader in over-the-counter and consumer products for men's and women's health and vitality with a growing product portfolio.

Company Overview

Innovus Pharmaceuticals Inc. (OTCQB: INNV) is an emerging leader in over-the-counter and consumer products for men's and women's health and vitality. These products are marketed in the U.S. and Canada through retailers and on the web.

The company's growing product portfolio includes Zestra for female arousal and desire, EjectDelay for premature ejaculation, Sensum to increase penile sensitivity, Vesele to promote sexual and cognitive health, and Zestra Glide for female lubrication. In total, the company has 13 commercial products that are on the market.

In addition, the company is actively seeking an ANDA from the FDA for FlutiCare, which is a nasal spray for the management of seasonal and perennial allergic and non-allergic rhinitis.

Investment Highlights

  • Large End Markets. Innovus Pharmaceuticals Inc. is targeting multiple end markets worth more than $3 billion in aggregate, including the $1 billion female sexual dysfunction market, the $1 billion premature ejaculation market, and the $1 billion allergic rhinitis market, with innovative and proven products.
  • Extensive Distribution. The company's products are sold in most major big box U.S. retailers, including Walmart, Target, Kroger, Sears, and Fred Meyer. In addition, the company has an international presence in over 60 countries through 10 distribution partners across the Americas, Africa, Europe, and Asia.
  • Growing Pipeline. The company has 13 commercial products in its portfolio with three pipeline products with significant potential. Furthermore, the company acquired Beyond Human in March of 2016 to expand into the testosterone marketplace and signed eight commercial partnerships to expand its reach.
  • Improving Financials. The company raised nearly $2.5 million and repaid all of its outstanding and due debt. Management anticipates becoming cash flow positive in 2016 and profitable in 2017.

Download the Complete INNV Company Analysis

Report

Download a free SECFilings Company Analysis on Innovus Pharmaceuticals Inc. that covers:

  • Recent Developments - A review of recent developments and their impact on the company's bottom line.
  • Financial Analysis - A detailed review of the company's income statement, balance sheet, and cash flow statement.
  • Peer Comparison - A detailed list of industry peers and the company's relative valuation, growth rates, and much more.

Enter your e-mail below to receive the free analysis:

I also want to receive reports on similar opportunities in the space from time to time. We promise not to send spam.